Voyager reports promising data for early stage trial in Alzheimer’s disease treatment
Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...
Voyager Therapeutics announces data from SAD trial of VY7523
Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational ...
Insider Monkey22d
10 Cheap Biotech Stocks to Invest in Now
The company recently completed enrollment for its VY7523 trial for Alzheimer’s disease with data expected in 2025. The company’s strong financial position and promising Alzheimer’s program ...
Investing23d
Voyager Therapeutics shifts focus for ALS therapy
The firm specifically highlighted the potential of Voyager's tau-targeting therapies, VY7523 and VY1706, and its TRACER platform. Citi also initiated a Buy rating for Voyager, with a price target ...